Ceapro Inc V.CZO

New Press Release - Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings

TORONTO and EDMONTON, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that securityholders of both biopharmaceutical development companies approved the all-stock merger of...read article.

[lscfa]

Thumbs down

[lscfa]

15 million AEZS Shs o/s post merger. Are they really going to consolidate down to 4 or 5 million Shs?

[prophetoffactz]

This merger was put together at the bottom of the biotech market. They had to guarentee the new company wouldn't be up for listing review in a difficult market. If current market conditions are here to stay and AEZS/CZO clear the key hurdles immediately before them(diagnostic data, PGX scale-up, etc.) we could be talking share-splits.

[Ciao]

Absolutely. They need to get the share price up, else risk de-lisitng from NASDAQ. It's one big joke. You'll never get institutional interest with a tight share structure and don't expect an instituion to take part in any financings even after the rollback.  AEZS name and management has a great reputation for detroying shareholder value, they will only attract retails investors

[Ciao]

If you add the current market cap of both AEZS and CZO you will get about $30M CDN in total. Divide that by the 15M shares and you will end up with a share price of about $2 CDN / share. If the market is efficient that is what the share price would be about of the merged company. As $2 CDN or about $1.50 USD, the share price does not meet min. NASDAQ listing requirements if it stays prolonged at